Orlistat, a new lipase inhibitor for the management of obesity.
about
Obesity, nutrition, and liver disease in childrenThe DHR96 nuclear receptor controls triacylglycerol homeostasis in Drosophila.Gelidium elegans Regulates the AMPK-PRDM16-UCP-1 Pathway and Has a Synergistic Effect with Orlistat on Obesity-Associated Features in Mice Fed a High-Fat DietEffect of dietary soluble fiber on neurohormonal profiles in serum and brain of rats.Anti-obesity effects of Lysimachia foenum-graecum characterized by decreased adipogenesis and regulated lipid metabolism.The appropriateness of routine medication treatment for schizophrenia.Cell-intrinsic lysosomal lipolysis is essential for alternative activation of macrophagesOrlistat use in type 2 diabetes.Management of obesity as a chronic disease: nonpharmacologic, pharmacologic, and surgical options.New pharmacological tools for obesity.Banting lecture 2011: hyperinsulinemia: cause or consequence?Analysis of dietary insoluble and soluble fiber contents in school meal.Efficacy of orlistat as an adjunct to behavioral treatment in overweight African American and Caucasian adolescents with obesity-related co-morbid conditions.Whittling away at obesity and overweight. Small lifestyle changes can have the biggest impact.Ageing and metabolism: drug discovery opportunities.Loss of BOSS Causes Shortened Lifespan with Mitochondrial Dysfunction in DrosophilaSurgery for obesity: panacea or Pandora's box?A novel APOC2 gene mutation identified in a Chinese patient with severe hypertriglyceridemia and recurrent pancreatitisAcinetobacter baumannii Is Dependent on the Type II Secretion System and Its Substrate LipA for Lipid Utilization and In Vivo FitnessVeratri Nigri Rhizoma et Radix (Veratrum nigrum L.) and Its Constituent Jervine Prevent Adipogenesis via Activation of the LKB1-AMPKα-ACC Axis In Vivo and In Vitro.Antiadipogenic Effects of Aster glehni Extract: In Vivo and In Vitro Effects.Interaction of Veratrum nigrum with Panax ginseng against Obesity: A Sang-ban Relationship.Critical role of fatty acid metabolism in ILC2-mediated barrier protection during malnutrition and helminth infectionEffectiveness of a psychosocial weight management program for individuals with schizophreniaAnti-obesity effects of black ginseng extract in high fat diet-fed miceCost-effectiveness of pharmacological anti-obesity treatments: a systematic review.Review paper: Current strategies in the development of anti-obesity drugs and their safety concerns.Weight control interventions improve therapeutic efficacy of dacarbazine in melanoma by reversing obesity-induced drug resistanceNonalcoholic Steatohepatitis: Clinical Presentation, Diagnosis, and Treatment.Comparative Evaluation of Sulfur Compounds Contents and Antiobesity Properties of Allium hookeri Prepared by Different Drying MethodsObesity in heart failure: impact on survival and treatment modalities.New pharmacological treatments for the management of obesity.Epidemiology of Obesity and Pharmacologic Treatment Options.Anti-obesity activities of the yoshinone A and the related marine γ-pyrone compounds.Inhibitory effects of Aster spathulifolius extract on adipogenesis and lipid accumulation in 3T3-L1 preadipocytes.Commentary on prevention a possible drug-drug interaction: is concurrent administration of orlistat and pioglitazone increase the risk of durg-induced hepatotoxicity?Triglyceride Treatment in the Age of Cholesterol Reduction.Zebrafish lipid droplets regulate embryonic ATP homeostasis to power early development.Multi-Targeted Molecular Effects of Hibiscus sabdariffa Polyphenols: An Opportunity for a Global Approach to Obesity.Anti-obesity effects of Boussingaulti gracilis Miers var. pseudobaselloides Bailey via activation of AMP-activated protein kinase in 3T3-L1 cells.
P2860
Q27002523-873B4E2D-688F-4771-A4FA-1981A4D4DC6CQ33577156-0A4485EA-103B-4B1E-ADE7-043B207F52ACQ33616651-E0B604E8-5951-4FD9-8DD3-62A90F401D9BQ33767578-A4827977-6488-4EFC-BCBF-D40382666159Q33841823-292B5F3B-8756-45AD-B40E-DAC520F8CA5AQ33950877-8F7EA1E4-BECA-4AD8-9ED8-F311DE2C1B5AQ34071063-335D4AE5-DAB7-4517-885C-297BCC0D2818Q34709845-A14CBB7F-CE29-4828-9178-64CD0683B6BBQ35029802-3A5E7EC4-8322-4B13-8269-580D690FAAE2Q35037275-14624F14-6B0F-4DAC-A919-3AFE39736FFDQ35612356-FD89AE36-3BEA-4BB5-B561-362F43B73F34Q35813012-BAA76923-781D-4722-BE45-6EFC2D353760Q35926351-3BA76673-F6A7-4097-AF2A-C48372141687Q36021047-FC946C8B-74E9-4DEF-985D-1E6E853B7B4CQ36174012-48B742FE-1AAA-4700-9C0E-A0DF8D6FF5E6Q36238145-F83437D5-5579-456A-9DC8-C15963BAF1A8Q36459084-B12C8557-0DDF-4FF6-802C-30304AB94B38Q36468985-A4169CDC-9770-4DA9-AF82-7145C4877678Q36575078-B0292BC3-700D-4C50-B20A-6D21E8E3824CQ36814522-33F902CC-244A-4925-B78C-63AEFA94DB90Q36995285-888C1BD8-EB52-40B9-BA34-121AB5A5B952Q37173554-947366E7-8168-45A7-B308-6269ECA4B424Q37178981-577C8112-611B-4929-9D94-62E760C9CB8BQ37257633-4DDD8449-E24B-4533-9FEE-469FABCBE75BQ37283794-31922429-D145-42D2-A096-E3F165EACB82Q37316553-66060D8C-02A7-4D44-BC5E-1CA60406F8FDQ37359377-11E8191C-BC11-4BD9-8411-A38C495AB96EQ37480946-A01C282A-013C-4892-94E3-2A01F6DE4C10Q37699734-D56A867E-1903-475F-816B-4E3D339F0028Q37733567-E5FA0AB7-0B45-4604-8606-C6EEAAA8C12CQ38128922-C08D7CB8-1357-4DB4-8479-F9500FCF18A9Q38211754-66957408-B5E1-4E14-A42B-143BA11AC433Q38717129-C7917FE0-BFE1-40B4-9615-B3174FE9A3D3Q38789788-FC81675F-D9E6-45FE-87B4-D3D2971A091EQ38827616-1C3148CD-ADBA-4275-AE8C-E48EC53B4430Q38897647-EDC05E65-B1EB-4A4F-84BD-38C0F36CBB43Q38932760-00C6E7A5-4E14-4917-A04C-002847308EF2Q41225348-4AF15072-3750-4793-A961-F7A18A73A074Q41584436-5219386B-74C1-4768-9070-1B908592A0E9Q42321603-5B75B041-A174-4834-AC9F-6752B1936D02
P2860
Orlistat, a new lipase inhibitor for the management of obesity.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Orlistat, a new lipase inhibitor for the management of obesity.
@ast
Orlistat, a new lipase inhibitor for the management of obesity.
@en
type
label
Orlistat, a new lipase inhibitor for the management of obesity.
@ast
Orlistat, a new lipase inhibitor for the management of obesity.
@en
prefLabel
Orlistat, a new lipase inhibitor for the management of obesity.
@ast
Orlistat, a new lipase inhibitor for the management of obesity.
@en
P2860
P1433
P1476
Orlistat, a new lipase inhibitor for the management of obesity.
@en
P2093
P2860
P304
P356
10.1592/PHCO.20.4.270.34882
P407
P577
2000-03-01T00:00:00Z